Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
University of Chicago
University of Chicago
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OHSU Knight Cancer Institute
University Hospital, Ghent